Amgen received two recommendations from European regulators that would allow label changes to cardiovascular drug Repatha and biosimilar cancer treatment AB 980. The European Medicines Agency Committee for Medicinal Products for Human Use, or CHMP, released a positive opinion March 23 for Repatha, stating that it could help reduce the risk of heart attack or…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
